Tagged: gene-editing
11 results
Colossal Biosciences
Colossal Biosciences is a Dallas-based genetic engineering company using de-extinction science - ancient DNA, CRISPR gene editing, and reproductive technology - to revive lost species like the woolly mammoth, thylacine, dodo, and dire wolf, and to apply the same tools to protecting endangered wildlife. Co-founded in 2021 by tech entrepreneur Ben Lamm and Harvard geneticist George Church, it became Texas' first decacorn with a $10.2 billion valuation and has spun out companies in computational biology and plastic degradation.
AvenCell Therapeutics
AvenCell Therapeutics is a clinical-stage cell therapy company building switchable, universal CAR-T treatments that can be turned 'off' and 'on' even after they are inside a patient. By pairing this controllable switch with a CRISPR-engineered, off-the-shelf allogeneic platform, AvenCell aims to widen the narrow safety window of conventional CAR-T while cutting the cost and wait time of manufacturing, targeting hard-to-treat blood cancers like AML, B-cell malignancies and, increasingly, autoimmune disease.
GentiBio
GentiBio is a clinical-stage biotechnology company in Cambridge, Massachusetts building engineered regulatory T cell (EngTreg) therapies designed to restore immune tolerance and durably treat autoimmune, autoinflammatory, alloimmune, and allergic diseases. Spun out of research from Seattle Children's, Benaroya Research Institute, and MIGAL Galilee Research Institute, the company combines gene editing of FOXP3 with a modular Treg engineering and manufacturing platform. Its lead program, GNTI-122, is an autologous antigen-specific Treg therapy for recently diagnosed type 1 diabetes now in a Phase 1 trial (POLARIS). GentiBio has raised roughly $177M and signed a partnership with Bristol Myers Squibb worth up to $1.9B in potential milestones.
BreezeBio
BreezeBio (formerly GenEdit) is a Brisbane, California-based biotechnology company that develops precision genetic medicines using its proprietary NanoGalaxy platform - a library of polymer nanoparticles capable of delivering genetic payloads like mRNA, siRNA, and CRISPR components to specific tissues without triggering immune responses. Unlike viral vectors that can only be dosed once and often provoke dangerous immune reactions, BreezeBio's non-viral approach allows repeat dosing, broad payload flexibility, and tissue selectivity across immune cells, heart, lung, and CNS. Founded in 2016 out of UC Berkeley by CEO Dr. Kunwoo Lee and CTO Dr. Hyo Min Park, the company rebranded from GenEdit in early 2026 following its $60M Series B, signaling a shift from delivery-platform licensor to full therapeutic developer with a lead program (BRZ-101) targeting Type 1 Diabetes.
Mammoth Biosciences
Mammoth Biosciences is a Brisbane, California biotechnology company co-founded by Nobel laureate Jennifer Doudna that develops ultracompact CRISPR systems for both in vivo gene-editing therapeutics and rapid molecular diagnostics. Its proprietary toolbox of small Cas enzymes (including Cas14 and CasΦ) powers therapeutic partnerships with Regeneron, Vertex and Bayer, while the DETECTR platform brings CRISPR-based disease detection out of the central lab.
Profluent
Profluent is an AI-first protein design company building frontier models that author novel proteins - including the first AI-designed CRISPR gene editor, OpenCRISPR-1. Based in Berkeley's biotech corridor, the company applies the same scaling-law playbook that worked for language models to the language of biology, then validates the outputs in a wet lab.
Ali Madani
Ali Madani is the founder and CEO of Profluent, the AI-first protein design company based in Emeryville, California. A machine learning researcher by training, he holds a PhD from UC Berkeley and pioneered the use of large language models to generate functional proteins from scratch - first at Salesforce AI Research as the architect of ProGen, then at Profluent where his team created OpenCRISPR-1, the world's first AI-designed and open-source gene editor, published in Nature in 2025. With $150M in total funding from Bezos Expeditions, Altimeter Capital, Spark Capital, and Insight Partners, Madani is on a mission to make biology programmable - designing proteins that don't exist in nature to solve the biggest challenges in human health, agriculture, and biomanufacturing.
Kunwoo Lee
Kunwoo Lee is the CEO and Co-founder of BreezeBio (formerly GenEdit), a Brisbane, California-based biotech company pioneering non-viral gene delivery through its proprietary NanoGalaxy platform. A Siebel Scholar and Forbes 30 Under 30 honoree who earned his PhD from UC Berkeley-UCSF Joint Program in Bioengineering, Lee co-founded GenEdit in 2016 alongside Professor Niren Murthy and fellow researcher Hyo Min Park, building out a polymer nanoparticle library of thousands of chemically distinct compounds capable of delivering diverse genetic payloads to specific tissues. The company has raised over $118 million including a $60M Series B in February 2026, struck a landmark $644M collaboration deal with Genentech, and rebranded to BreezeBio to signal its pivot from platform company to clinical-stage therapeutics developer advancing BRZ-101 for Type 1 Diabetes.
Trevor Martin
Trevor Martin is the co-founder and CEO of Mammoth Biosciences, the CRISPR company he built alongside Nobel laureate Jennifer Doudna and two of her graduate students. A Princeton-trained computational biologist who earned his PhD at Stanford, Martin turned a cold email to Doudna into a $465M-funded platform company developing ultracompact CRISPR systems - including NanoCas, the first efficient extrahepatic gene editor - aimed at permanently curing genetic diseases.
Steven Banerjee
Steven Banerjee is the Founder and CEO of Nextnet, a life sciences AI platform that organizes and connects the world's biomedical knowledge. A serial biotech entrepreneur originally from New Zealand, he trained as a mechanical engineer at the University of Canterbury, served as a Doctoral Fellow at IBM Labs, and collaborated with gene sequencing pioneer Ron Davis at Stanford before founding his first venture, Mekonos - a cell and gene therapy company that raised over $40 million and was acquired. He then founded Nextnet in late 2020 to bring AI-native research tools to scientists, building a platform now used across 100+ countries by researchers at Harvard, MIT, MD Anderson, and UCSF. Nextnet's Copilot and Explorer tools are powered by a purpose-built biomedical ontology unifying data from PubMed, ChEMBL, Ensembl, and millions of scientific sources.
Tom Cahill
Thomas J. Cahill, MD, PhD is the founder and managing partner of Newpath Partners, a Boston-based life sciences venture firm he built from the ground up to translate breakthrough academic science into medicines. A structural biologist trained under two Nobel laureates, Cahill has co-founded more than a dozen biotech companies — including Prime Medicine, Chroma Medicine, and Autobahn Therapeutics — and became one of the pandemic's most consequential behind-the-scenes operators when he assembled Scientists to Stop COVID-19, a coalition that fed curated research directly to the White House and helped redirect Regeneron's manufacturing to Dublin.